A tetraspecific VHH-based neutralizing antibody modifies disease outcome in three animal models of clostridium difficile infection

Clinical and Vaccine Immunology

Volumn 23, Issue 9, 2016, Pages 774-784

  Schmidt, Diane J ^a   Beamer, Gillian ^a   Tremblay, Jacqueline M ^a   Steele, Jennifer A ^a   Kim, Hyeun Bum ^b   Wang, Yaunkai ^c   Debatis, Michele ^a   Sun, Xingmin ^a   Kashentseva, Elena A ^d   Dmitriev, Igor P ^d   Curiel, David T ^d   Shoemaker, Charles B ^a   Tzipori, Saul ^a  

^a TUFTS UNIVERSITY   (United States)

^b Dankook University   (South Korea)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; NEUTRALIZING ANTIBODY; VIRULENCE FACTOR; ANTITOXIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; DRUG CARRIER; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GNOTOBIOTICS; HEAVY CHAIN; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PIGLET; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYRIAN HAMSTER; VIRAL GENE THERAPY; ADENOVIRIDAE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CLOSTRIDIUM INFECTIONS; DISEASE MODEL; GENE THERAPY; GENETICS; ISOLATION AND PURIFICATION; MESOCRICETUS; MICROBIOLOGY; PIG; PRECLINICAL STUDY; PROCEDURES; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; ENTEROTOXINS; GENETIC THERAPY; MESOCRICETUS; MICE, INBRED C57BL; SWINE; TREATMENT OUTCOME;

EID: 84987642620     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00730-15     Document Type: Article

References (76)

1. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526-536. http://dx.doi.org/10.1038/nrmicro2164
2. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. 2009. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 37:263-270. http://dx.doi.org/10.1016/j.ajic.2009.01.001
3. Bartlett JG, Perl TM. 2005. The new Clostridium difficile-what does it mean? N Engl J Med 353:2503-2505. http://dx.doi.org/10.1056/NEJMe058221
4. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. 2010. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23:529-549. http://dx.doi.org/10.1128/CMR.00082-09
5. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. 2008. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 122:1266-1270. http://dx.doi.org/10.1542/peds.2008-0469
6. Pituch H. 2009. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 33(Suppl):S42-S45. http://dx.doi.org/10.1016/S0924-8579(09)70016-0
7. Sunenshine RH, McDonald LC. 2006. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 73:187-197. http://dx.doi.org/10.3949/ccjm.73.2.187
8. Higa JT, Kelly CP. 2014. New drugs and strategies for management of Clostridium difficile colitis. J Intensive Care Med 29:190-199. http://dx.doi.org/10.1177/0885066613475426
9. Durai R. 2007. Epidemiology, pathogenesis, and management of Clostridium difficile infection. Dig Dis Sci 52:2958-2962. http://dx.doi.org/10.1007/s10620-006-9626-y
10. Lyerly DM, Krivan HC, Wilkins TD. 1988. Clostridium difficile: its disease and toxins. Clin Microbiol Rev 1:1-18. http://dx.doi.org/10.1128/CMR.1.1.1
11. Bartlett JG. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145:758-764. http://dx.doi.org/10.7326/0003-4819-145-10-200611210-00008
12. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:247-263. http://dx.doi.org/10.1128/CMR.18.2.247-263.2005
13. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile- associated diarrhea, stratified by disease severity. Clin Infect Dis 45: 302-307. http://dx.doi.org/10.1086/519265
14. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. 2000. Epidemiology of recurrences or reinfections of Clostridium difficileassociated diarrhea. J Clin Microbiol 38:2386-2388
15. Brown AT, Seifert CF. 2014. Effect of treatment variation on outcomes in patients with Clostridium difficile. Am J Med 127:865-870. http://dx.doi.org/10.1016/j.amjmed.2014.05.016
16. Giannasca PJ, Warny M. 2004. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 22:848-856. http://dx.doi.org/10.1016/j.vaccine.2003.11.030
17. Scott LJ. 2013. Fidaxomicin: a review of its use in patients with Clostridium difficile infection. Drugs 73:1733-1747. http://dx.doi.org/10.1007/s40265-013-0134-z
18. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D. 2013. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382: 1249-1257. http://dx.doi.org/10.1016/S0140-6736(13)61218-0
19. Allen SJ, Wareham K, Wang D, Bradley C, Sewell B, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D, Phillips CJ. 2013. A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, doubleblind, placebo-controlled, parallel arm trial (PLACIDE). Health Technol Assess 17:1-140
20. Gorbach SL. 2000. Probiotics and gastrointestinal health. Am J Gastroenterol 95:S2-S4. http://dx.doi.org/10.1016/S0002-9270(99)00806-0
21. Maziade PJ, Andriessen JA, Pereira P, Currie B, Goldstein EJ. 2013. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 29:1341-1347. http://dx.doi.org/10.1185/03007995.2013.833501
22. Pattani R, Palda VA, Hwang SW, Shah PS. 2013. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med 7:e56-e67.
23. Rainkie D, Kolber MR. 2013. Probiotics for the prevention of Clostridium difficile. Can Fam Physician 59:957
24. MacConnachie AA, Fox R, Kennedy DR, Seaton RA. 2009. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 102:781-784. http://dx.doi.org/10.1093/qjmed/hcp118
25. Rubin TA, Gessert CE, Aas J. 2009. Stool transplantation for older patients with Clostridium difficile infection. J Am Geriatr Soc 57:2386. http://dx.doi.org/10.1111/j.1532-5415.2009.02600.x
26. Vindigni SM, Broussard EK, Surawicz CM. 2013. Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol 7:615-628. http://dx.doi.org/10.1586/17474124.2013.832501
27. Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, Acheson DW, Fitzpatrick R, Kelly P, Shackett K, Papoulis AT, Goddard PJ, Barker RH, Jr, Palace GP, Klinger JD. 2001. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 45:2340-2347. http://dx.doi.org/10.1128/AAC.45.8.2340-2347.2001
28. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. 2009. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 27:3598-3604. http://dx.doi.org/10.1016/j.vaccine.2009.03.058
29. Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, Rollins SM, Qadri F, Calderwood SB, Kelly CP, Ryan ET. 2007. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun 75:2826-2832. http://dx.doi.org/10.1128/IAI.00127-07
30. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP. 2005. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128:764-770. http://dx.doi.org/10.1053/j.gastro.2004.11.004
31. Abougergi MS, Kwon JH. 2011. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 56:19-26. http://dx.doi.org/10.1007/s10620-010-1411-2
32. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74:6339-6347. http://dx.doi.org/10.1128/IAI.00982-06
33. Demarest SJ, Hariharan M, Elia M, Salbato J, Jin P, Bird C, Short JM, Kimmel BE, Dudley M, Woodnutt G, Hansen G. 2010. Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs 2:190-198. http://dx.doi.org/10.4161/mabs.2.2.11220
34. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969. http://dx.doi.org/10.1016/j.vaccine.2009.10.144
35. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197-205. http://dx.doi.org/10.1056/NEJMoa0907635
36. Mulvey GL, Dingle TC, Fang L, Strecker J, Armstrong GD. 2011. Therapeutic potential of egg yolk antibodies for treating Clostridium difficile infection. J Med Microbiol 60:1181-1187. http://dx.doi.org/10.1099/jmm.0.029835-0
37. Saito T, Kimura S, Tateda K, Mori N, Hosono N, Hayakawa K, Akasaka Y, Ishii T, Sumiyama Y, Kusachi S, Nagao J, Yamaguchi K. 2011. Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice. J Antimicrob Chemother 66:1096-1099. http://dx.doi.org/10.1093/jac/dkr027
38. Andersen KK, Strokappe NM, Hultberg A, Truusalu K, Smidt I, Mikelsaar RH, Mikelsaar M, Verrips T, Hammarstrom L, Marcotte H. 2015. Neutralization of Clostridium difficile toxin B mediated by engineered lactobacilli producing single-domain antibodies. Infect Immun 84:395-406
39. Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, MacKenzie R, Tanha J. 2011. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem 286:8961-8976. http://dx.doi.org/10.1074/jbc.M110.198754
40. Taylor CP, Tummala S, Molrine D, Davidson L, Farrell RJ, Lembo A, Hibberd PL, Lowy I, Kelly CP. 2008. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 26:3404-3409. http://dx.doi.org/10.1016/j.vaccine.2008.04.042
41. Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, Piepenbrink KH, Sundberg EJ, Kelly CP, Bai G, Shoemaker CB, Feng H. 2014. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis 210:964-972. http://dx.doi.org/10.1093/infdis/jiu196
42. Kociolek LK, Gerding DN. 2016. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol 13:150-160. http://dx.doi.org/10.1038/nrgastro.2015.220
43. Steele J, Mukherjee J, Parry N, Tzipori S. 2013. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 207:323-330. http://dx.doi.org/10.1093/infdis/jis669
44. Kuehne SA, Cartman ST, Minton NP. 2011. Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes 2:252-255. http://dx.doi.org/10.4161/gmic.2.4.16109
45. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179. http://dx.doi.org/10.1038/nature07822
46. Young VB, Hanna PC. 2014. Overlapping roles for toxins in Clostridium difficile infection. J Infect Dis 209:9-11. http://dx.doi.org/10.1093/infdis/jit461
47. Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB. 2007. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods 324:13-25. http://dx.doi.org/10.1016/j.jim.2007.04.008
48. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. 1997. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414:521-526. http://dx.doi.org/10.1016/S0014-5793(97)01062-4
49. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L, Matagne A. 2002. Singledomain antibody fragments with high conformational stability. Protein Sci 11:500-515
50. van der Linden RH, Frenken LG, de Geus B, Harmsen MM, Ruuls RC, Stok W, de Ron L, Wilson S, Davis P, Verrips CT. 1999. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1431:37-46. http://dx.doi.org/10.1016/S0167-4838(99)00030-8
51. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, Tzipori S, Shoemaker CB. 2012. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One 7:e29941. http://dx.doi.org/10.1371/journal.pone.0029941
52. Vance DJ, Tremblay JM, Mantis NJ, Shoemaker CB. 2013. Stepwise engineering of heterodimeric single domain camelidVHHantibodies that passively protect mice from ricin toxin. J Biol Chem 288:36538-36547. http://dx.doi.org/10.1074/jbc.M113.519207
53. Tremblay JM, Mukherjee J, Leysath CE, Debatis M, Ofori K, Baldwin K, Boucher C, Peters R, Beamer G, Sheoran A, Bedenice D, Tzipori S, Shoemaker CB. 2013. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun 81:4592-4603. http://dx.doi.org/10.1128/IAI.01033-13
54. Moayeri M, Leysath CE, Tremblay JM, Vrentas C, Crown D, Leppla SH, Shoemaker CB. 2015. A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model. J Biol Chem 290:6584-6595. http://dx.doi.org/10.1074/jbc.M114.627943
55. Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. 2014. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis 209:83-86. http://dx.doi.org/10.1093/infdis/jit426
56. Yang Z, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis HG, Lee D, Hernandez LD, Seghezzi W, Furneisen JM, Davis NM, Therien AG, Feng H. 2015. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and be- zlotoxumab. Infect Immun 83:822-831. http://dx.doi.org/10.1128/IAI.02897-14
57. Herrera C, Tremblay JM, Shoemaker CB, Mantis NJ. 2015. Mechanisms of ricin toxin neutralization revealed through engineered homodimer camelid antibodies. J Biol Chem 290:27880-27889
58. Tremblay JM, Kuo CL, Abeijon C, Sepulveda J, Oyler G, Hu X, Jin MM, Shoemaker CB. 2010. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 56:990-998. http://dx.doi.org/10.1016/j.toxicon.2010.07.003
59. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, Vogelstein B, He TC. 2007. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2:1236-1247. http://dx.doi.org/10.1038/nprot.2007.135
60. Mukherjee J, Dmitriev I, Debatis M, Tremblay JM, Beamer G, Kashentseva EA, Curiel DT, Shoemaker CB. 2014. Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS One 9:e106422. http://dx.doi.org/10.1371/journal.pone.0106422
61. Sheoran AS, Dmitriev IP, Kashentseva EA, Cohen O, Mukherjee J, Debatis M, Shearer J, Tremblay JM, Beamer G, Curiel DT, Shoemaker CB, Tzipori S. 2015. Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication. Infect Immun 83:286-291. http://dx.doi.org/10.1128/IAI.02360-14
62. Maizel JV, Jr, White DO, Scharff MD. 1968. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36:115-125
63. Moayeri M, Tremblay JM, Debatis M, Dmietriev IP, Kashentseva EA, Yeh AJ, Cheung GY, Curiel DT, Leppla S, Shoemaker CB. 2016. Adenoviral expression of a bispecific VHH-based neutralizing agent that targets protective antigen provides prophylactic protection from anthrax in mice. Clin Vaccine Immunol 23:213-218. http://dx.doi.org/10.1128/CVI.00611-15
64. Sponseller JK, Steele JA, Schmidt DJ, Kim HB, Beamer G, Sun X, Tzipori S. 2015. Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. J Infect Dis 211:1334-1341
65. Tzipori S, Gunzer F, Donnenberg MS, de Montigny L, Kaper JB, Donohue-Rolfe A. 1995. The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection. Infect Immun 63:3621-3627
66. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10.1053/j.gastro.2008.09.002
67. Killgore G, Thompson A, Johnson S, Brazier J, Kuijper E, Pepin J, Frost EH, Savelkoul P, Nicholson B, van den Berg RJ, Kato H, Sambol SP, Zukowski W, Woods C, Limbago B, Gerding DN, McDonald LC. 2008. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 46:431-437. http://dx.doi.org/10.1128/JCM.01484-07
68. Douce G, Goulding D. 2010. Refinement of the hamster model of Clostridium difficile disease. Methods Mol Biol 646:215-227. http://dx.doi.org/10.1007/978-1-60327-365-7-14
69. Steele J, Chen K, Sun X, Zhang Y, Wang H, Tzipori S, Feng H. 2012. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis 205:384-391. http://dx.doi.org/10.1093/infdis/jir748
70. Steele J, Feng H, Parry N, Tzipori S. 2010. Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis 201:428-434. http://dx.doi.org/10.1086/649799
71. Cohen OR, Steele JA, Zhang Q, Schmidt DJ, Wang Y, Hamel PE, Beamer G, Xu B, Tzipori S. 2014. Systemically administered IgG antitoxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. PLoS One 9:e111075. http://dx.doi.org/10.1371/journal.pone.0111075
72. Nguyen A, Reyes AE, II, Zhang M, McDonald P, Wong WL, Damico LA, Dennis MS. 2006. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 19:291-297
73. Buckley AM, Spencer J, Candlish D, Irvine JJ, Douce GR. 2011. Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291. J Med Microbiol 60:1174-1180. http://dx.doi.org/10.1099/jmm.0.028514-0
74. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P. 2010. Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 3:49-56. http://dx.doi.org/10.1038/mi.2009.116
75. Lu ZH, Kaliberov S, Zhang J, Muz B, Azab AK, Sohn RE, Kaliberova L, Du Y, Curiel DT, Arbeit JM. 2014. The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting. Lab Invest 94:881-892. http://dx.doi.org/10.1038/labinvest.2014.78
76. Tang SC, Sambanis A, Sibley E. 2005. Proteasome modulating agents induce rAAV2-mediated transgene expression in human intestinal epithelial cells. Biochem Biophys Res Commun 331:1392-1400. http://dx.doi.org/10.1016/j.bbrc.2005.03.245